2017
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy
Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy. Circulation 2017, 136: 2210-2219. PMID: 29084735, PMCID: PMC5716860, DOI: 10.1161/circulationaha.117.028430.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAtherosclerosisCost-Benefit AnalysisDrug CostsElectronic Health RecordsEligibility DeterminationFemaleHumansHyperlipoproteinemia Type IIHypolipidemic AgentsInsurance, Health, ReimbursementInsurance, Pharmaceutical ServicesMaleMedicareMiddle AgedPCSK9 InhibitorsProcess Assessment, Health CareProprotein Convertase 9Retrospective StudiesSerine Proteinase InhibitorsTreatment OutcomeUnited StatesConceptsProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsAtherosclerotic cardiovascular diseasePCSK9i prescriptionsPayer typeCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 inhibitor therapyHigher low-density lipoprotein cholesterol levelsSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol levelsClinical atherosclerotic cardiovascular diseaseDrug's high costNonprimary care providersLipoprotein cholesterol levelsDescriptive cohort studyElectronic medical recordsPCSK9i therapyPrescription approvalThird-party payersStatin useClinical characteristicsStatin intoleranceCohort studyInhibitor therapyPharmacy claimsPrescription claimsSerum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study
Faridi KF, Zhao D, Martin SS, Lupton JR, Jones SR, Guallar E, Ballantyne CM, Lutsey PL, Michos ED. Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study. Nutrition 2017, 38: 85-93. PMID: 28526388, PMCID: PMC5443111, DOI: 10.1016/j.nut.2017.01.008.Peer-Reviewed Original ResearchConceptsIncident dyslipidemiaLipid changesLongitudinal community-based studyAdjusted average differencesDemographic-adjusted modelsLipid-lowering therapySerum vitamin DCommunity-based studyBaseline dyslipidemiaLipid trendsIncident useCardiovascular riskClinical characteristicsSD ageVitamin DARIC studyAtherosclerosis RiskCardiovascular diseaseLipid levelsDyslipidemiaCommunity studyRatio of TCHDLMixed effects modelsBaseline
2016
Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction
Faridi KF, Peterson ED, McCoy LA, Thomas L, Enriquez J, Wang TY. Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction. JAMA Cardiology 2016, 1: 147. PMID: 27437885, DOI: 10.1001/jamacardio.2016.0001.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMedication adherenceClinic visitsHospital dischargeMyocardial infarctionIntervention Outcomes Network RegistryPlatelet P2Y12 receptor inhibitorsAngiotensin-converting enzyme inhibitorAcute Coronary TreatmentFirst outpatient followImproved care transitionsP2Y12 receptor inhibitorsPostdischarge Follow-upAngiotensin receptor blockersSecondary prevention therapiesLong-term prognosisLow medication adherencePatient medication adherenceProportion of daysLower household incomeGuidelines hospitalsReceptor blockersAcute MIClinical characteristicsCoronary Treatment